Search





Search





Markets
/
Stocks
/
tech
/

Bio-Techne Corp

TECH

Add to Watchlist

71.600USD

-0.170-0.24%

Close 07-24 16:00（ET）Quotes delayed by 15 min

11.15BMarket Cap

101.45P/E TTM

Bio-Techne Corp

71.600

-0.170-0.24%

Overview

Financials

Discussions

Analysis

Company

View Detailed Chart

TradingKey Chart

Intraday

30m

Today

-0.24%

5 Days

-0.72%

1 Month

+0.85%

6 Months

+5.87%

Year to Date

+21.75%

1 Year

+21.81%

Key Figures

71.900Open

71.940High

2.07MVolume

101.45P/E TTM

34.44P/E Dynamic

0.320Dividend TTM

1.33%Turnover Ratio

71.770Prev. Close

71.580Low

106.25MTurnover

152.01P/E Static

5.67P/B

0.45%Div Yield TTM

4.22%ROA

72.16052wk High

0.73Volume Ratio

73.36MNet Profit

155.75MShares

0.7057EPS TTM

1.37Beta

5.34%ROE

43.19552wk Low

0.50%Amplitude

67.25%Gross Margin

11.15BMarket Cap

0.41Reward/Risk

2.66%Risk Rate

TradingKey Stock Score of Bio-Techne Corp

Currency: USD Updated: 2026-07-24

Key Insights

Bio-Techne Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 36 out of 386 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 70.30.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Bio-Techne Corp's Score

Industry at a Glance

Industry Ranking

36 / 386

Overall Ranking

93 / 4279

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Bio-Techne Corp Highlights

StrengthsRisks

Bio-Techne Corporation develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, advanced tissue-based in-situ hybridization assays and instrumentation for spatial genomic and tissue biopsy analysis and genetic and oncology kits for research and clinical applications. Its product portfolio and application enable scientific investigations into biological processes and molecular diagnostics and progression of specific diseases.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 68.69%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 68.69%.

Overvalued

The company’s latest PE is 101.45, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 178.19M shares, increasing 0.00% quarter-over-quarter.

Held by Lee Ainslie

Star Investor Lee Ainslie holds 5.14M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 2.68.

Analyst Rating

Based on 17 analysts

Hold

Current Rating

70.301

Target Price

-2.05%

Upside Space

Bio-Techne Corp News

Bio-Techne Acquired by Merck for $11.3 Billion at a Premium, Jumps Over 20% Premarket.

TradingKey - On June 25, Eastern Time, Germany's Merck Group announced that it will acquire US life sciences company Bio-Techne (TECH) for $73 per share in an all-cash transaction, representing an enterprise value of approximately $11.3 billion.

TradingKeyThu, Jun 25